ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-28F16700
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Influenza Vaccine Split Virion Inactivated Quadrivalent Market Research Report 2024
BUY CHAPTERS

Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-28F16700
Report
November 2025
Pages:138
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
SINOVAC BIOTECH
Sanofi
CSL Seqirus
GSK
Adimmune
Sinopharm
Jiangsu GDK Biotechnology
Abbott
Ab&B BIO-TECH
Hualan Bacterin
Ab&B BIO-TECH

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market

The global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent refers to an inactivated split influenza vaccine whose vaccine components include A (H3N2) subtype, A (H1N1) pdm09 subtype, and type B Victoria and Yamagata lines.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent leading manufacturers including Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH, etc., dominate supply; the top five capture approximately % of global revenue, with Hualan Bacterin leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Report

Report Metric Details
Report Name Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market
Segment by Type
  • Child
  • Adult
  • Elder
Segment by Application
  • Hospital
  • Clinic
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report?

Ans: The main players in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market are Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH

What are the Application segmentation covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report?

Ans: The Applications covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report are Hospital, Clinic

What are the Type segmentation covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report?

Ans: The Types covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report are Child, Adult, Elder

1 Study Coverage
1.1 Introduction to Influenza Vaccine (Split Virion), Inactivated, Quadrivalent: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Child
1.2.3 Adult
1.2.4 Elder
1.3 Market Segmentation by Application
1.3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Estimates and Forecasts 2020-2031
2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Estimates and Forecasts 2020-2031
2.4 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Child Market Size by Manufacturers
3.5.2 Adult Market Size by Manufacturers
3.5.3 Elder Market Size by Manufacturers
3.6 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Type (2020-2031)
6.4 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Type (2020-2031)
7.4 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Type (2020-2031)
9.4 Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Hualan Bacterin
11.1.1 Hualan Bacterin Corporation Information
11.1.2 Hualan Bacterin Business Overview
11.1.3 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.1.4 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Product in 2024
11.1.6 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application in 2024
11.1.7 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Area in 2024
11.1.8 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
11.1.9 Hualan Bacterin Recent Developments
11.2 Sinovac Biotech
11.2.1 Sinovac Biotech Corporation Information
11.2.2 Sinovac Biotech Business Overview
11.2.3 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.2.4 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Product in 2024
11.2.6 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application in 2024
11.2.7 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Area in 2024
11.2.8 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
11.2.9 Sinovac Biotech Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.3.4 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Product in 2024
11.3.6 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application in 2024
11.3.7 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Area in 2024
11.3.8 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 CSL Seqirus
11.4.1 CSL Seqirus Corporation Information
11.4.2 CSL Seqirus Business Overview
11.4.3 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.4.4 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Product in 2024
11.4.6 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application in 2024
11.4.7 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Area in 2024
11.4.8 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
11.4.9 CSL Seqirus Recent Developments
11.5 GSK
11.5.1 GSK Corporation Information
11.5.2 GSK Business Overview
11.5.3 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.5.4 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Product in 2024
11.5.6 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application in 2024
11.5.7 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Area in 2024
11.5.8 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
11.5.9 GSK Recent Developments
11.6 Adimmune
11.6.1 Adimmune Corporation Information
11.6.2 Adimmune Business Overview
11.6.3 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.6.4 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Adimmune Recent Developments
11.7 Sinopharm
11.7.1 Sinopharm Corporation Information
11.7.2 Sinopharm Business Overview
11.7.3 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.7.4 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Sinopharm Recent Developments
11.8 Jiangsu GDK Biotechnology
11.8.1 Jiangsu GDK Biotechnology Corporation Information
11.8.2 Jiangsu GDK Biotechnology Business Overview
11.8.3 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.8.4 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Jiangsu GDK Biotechnology Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview
11.9.3 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.9.4 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Abbott Recent Developments
11.10 Ab&B BIO-TECH
11.10.1 Ab&B BIO-TECH Corporation Information
11.10.2 Ab&B BIO-TECH Business Overview
11.10.3 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Models, Descriptions and Specifications
11.10.4 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Ab&B BIO-TECH Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industry Chain
12.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
SINOVAC BIOTECH
Sanofi
CSL Seqirus
GSK
Adimmune
Sinopharm
Jiangsu GDK Biotechnology
Abbott
Ab&B BIO-TECH
Hualan Bacterin
Ab&B BIO-TECH
List of Tables
 Table 1. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2020-2025) & (K Units)
 Table 8. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Share by Manufacturers (2020-2025)
 Table 12. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccine (Split Virion), Inactivated, Quadrivalent as of 2024)
 Table 16. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base and Headquarters
 Table 19. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2020-2025) & (K Units)
 Table 23. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2026-2031) & (K Units)
 Table 24. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2020-2025) & (K Units)
 Table 29. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2026-2031) & (K Units)
 Table 30. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Growth Accelerators and Market Barriers
 Table 37. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Growth Accelerators and Market Barriers
 Table 40. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Investment Opportunities and Key Challenges
 Table 47. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Hualan Bacterin Corporation Information
 Table 51. Hualan Bacterin Description and Major Businesses
 Table 52. Hualan Bacterin Product Models, Descriptions and Specifications
 Table 53. Hualan Bacterin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Hualan Bacterin Sales Value Proportion by Product in 2024
 Table 55. Hualan Bacterin Sales Value Proportion by Application in 2024
 Table 56. Hualan Bacterin Sales Value Proportion by Geographic Area in 2024
 Table 57. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
 Table 58. Hualan Bacterin Recent Developments
 Table 59. Sinovac Biotech Corporation Information
 Table 60. Sinovac Biotech Description and Major Businesses
 Table 61. Sinovac Biotech Product Models, Descriptions and Specifications
 Table 62. Sinovac Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Sinovac Biotech Sales Value Proportion by Product in 2024
 Table 64. Sinovac Biotech Sales Value Proportion by Application in 2024
 Table 65. Sinovac Biotech Sales Value Proportion by Geographic Area in 2024
 Table 66. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
 Table 67. Sinovac Biotech Recent Developments
 Table 68. Sanofi Corporation Information
 Table 69. Sanofi Description and Major Businesses
 Table 70. Sanofi Product Models, Descriptions and Specifications
 Table 71. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Sanofi Sales Value Proportion by Product in 2024
 Table 73. Sanofi Sales Value Proportion by Application in 2024
 Table 74. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 75. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
 Table 76. Sanofi Recent Developments
 Table 77. CSL Seqirus Corporation Information
 Table 78. CSL Seqirus Description and Major Businesses
 Table 79. CSL Seqirus Product Models, Descriptions and Specifications
 Table 80. CSL Seqirus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. CSL Seqirus Sales Value Proportion by Product in 2024
 Table 82. CSL Seqirus Sales Value Proportion by Application in 2024
 Table 83. CSL Seqirus Sales Value Proportion by Geographic Area in 2024
 Table 84. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
 Table 85. CSL Seqirus Recent Developments
 Table 86. GSK Corporation Information
 Table 87. GSK Description and Major Businesses
 Table 88. GSK Product Models, Descriptions and Specifications
 Table 89. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. GSK Sales Value Proportion by Product in 2024
 Table 91. GSK Sales Value Proportion by Application in 2024
 Table 92. GSK Sales Value Proportion by Geographic Area in 2024
 Table 93. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent SWOT Analysis
 Table 94. GSK Recent Developments
 Table 95. Adimmune Corporation Information
 Table 96. Adimmune Description and Major Businesses
 Table 97. Adimmune Product Models, Descriptions and Specifications
 Table 98. Adimmune Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Adimmune Recent Developments
 Table 100. Sinopharm Corporation Information
 Table 101. Sinopharm Description and Major Businesses
 Table 102. Sinopharm Product Models, Descriptions and Specifications
 Table 103. Sinopharm Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Sinopharm Recent Developments
 Table 105. Jiangsu GDK Biotechnology Corporation Information
 Table 106. Jiangsu GDK Biotechnology Description and Major Businesses
 Table 107. Jiangsu GDK Biotechnology Product Models, Descriptions and Specifications
 Table 108. Jiangsu GDK Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Jiangsu GDK Biotechnology Recent Developments
 Table 110. Abbott Corporation Information
 Table 111. Abbott Description and Major Businesses
 Table 112. Abbott Product Models, Descriptions and Specifications
 Table 113. Abbott Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Abbott Recent Developments
 Table 115. Ab&B BIO-TECH Corporation Information
 Table 116. Ab&B BIO-TECH Description and Major Businesses
 Table 117. Ab&B BIO-TECH Product Models, Descriptions and Specifications
 Table 118. Ab&B BIO-TECH Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Ab&B BIO-TECH Recent Developments
 Table 120. Key Raw Materials Distribution
 Table 121. Raw Materials Key Suppliers
 Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 123. Milestones in Production Technology Evolution
 Table 124. Distributors List
 Table 125. Market Trends and Market Evolution
 Table 126. Market Drivers and Opportunities
 Table 127. Market Challenges, Risks, and Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources


List of Figures
 Figure 1. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Picture
 Figure 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Child Product Picture
 Figure 4. Adult Product Picture
 Figure 5. Elder Product Picture
 Figure 6. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospital
 Figure 8. Clinic
 Figure 9. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Report Years Considered
 Figure 10. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Region (2020-2031)
 Figure 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (2020-2031) & (K Units)
 Figure 15. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 16. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Region (2020-2031)
 Figure 17. Top 5 and Top 10 Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume Market Share in 2024
 Figure 18. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. Child Revenue Market Share by Manufacturer in 2024
 Figure 21. Adult Revenue Market Share by Manufacturer in 2024
 Figure 22. Elder Revenue Market Share by Manufacturer in 2024
 Figure 23. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2020-2031)
 Figure 24. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type (2020-2031)
 Figure 25. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2020-2031)
 Figure 26. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2020-2031)
 Figure 27. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales YoY (2020-2031) & (K Units)
 Figure 28. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. North America Top 5 Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) in 2024
 Figure 30. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Type (2020- 2031)
 Figure 31. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 32. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Application (2020-2031)
 Figure 33. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 34. US Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 35. Canada Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 36. Mexico Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 37. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales YoY (2020-2031) & (K Units)
 Figure 38. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Europe Top 5 Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) in 2024
 Figure 40. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Type (2020-2031)
 Figure 41. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Application (2020-2031)
 Figure 43. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Germany Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 45. France Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 46. U.K. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 47. Italy Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 48. Russia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales YoY (2020-2031) & (K Units)
 Figure 50. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue YoY (2020-2031) & (US$ Million)
 Figure 51. Asia-Pacific Top 8 Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) in 2024
 Figure 52. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Type (2020- 2031)
 Figure 53. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 54. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Application (2020-2031)
 Figure 55. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Indonesia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 57. Japan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 58. South Korea Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 59. China Taiwan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 60. India Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2031) & (US$ Million)
 Figure 61. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales YoY (2020-2031) & (K Units)
 Figure 62. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Central and South America Top 5 Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) in 2024
 Figure 64. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Type (2021-2031)
 Figure 65. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Application (2020-2031)
 Figure 67. Central and South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 68. Brazil Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2025) & (US$ Million)
 Figure 69. Argentina Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2025) & (US$ Million)
 Figure 70. Middle East, and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales YoY (2020-2031) & (K Units)
 Figure 71. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue YoY (2020-2031) & (US$ Million)
 Figure 72. Middle East and Africa Top 5 Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) in 2024
 Figure 73. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Type (2021-2031)
 Figure 74. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 75. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Volume (K Units) by Application (2020-2031)
 Figure 76. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 77. GCC Countries Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2025) & (US$ Million)
 Figure 78. Turkey Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2025) & (US$ Million)
 Figure 79. Egypt Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2025) & (US$ Million)
 Figure 80. South Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (2020-2025) & (US$ Million)
 Figure 81. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industry Chain Mapping
 Figure 82. Regional Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base Distribution (%)
 Figure 83. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Market Share by Region (2020-2031)
 Figure 84. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Process
 Figure 85. Regional Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Cost Structure
 Figure 86. Channels of Distribution (Direct Vs Distribution)
 Figure 87. Bottom-up and Top-down Approaches for This Report
 Figure 88. Data Triangulation
 Figure 89. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Trivalent Split Influenza Vaccine Market Research Report 2025
Split Influenza Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tetravalent Influenza Virus Lysate Vaccine Market Research Report 2024
Global Inactivated Poultry Vaccine Market Research Report 2025
Global Influenza Subunit Vaccine Market Research Report 2024
Inactivated Vaccine Market
Reassortant Avian Influenza Virus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inactivated Influenza Virus Vaccine Market Research Report 2025
Global Trivalent Inactivated Influenza Vaccine Market Research Report 2025
Influenza Virus Vaccine H1N1 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multivalent Influenza Vaccines Market Research Report 2025
Global Vaccine for Influenza Market Research Report 2025
Global Pandemic Influenza Vaccine Market Research Report 2025
Global Adjuvanted Influenza Vaccine Market Research Report 2024
Global Equine Influenza Vaccine Market Research Report 2024
Inactivated Influenza Vaccine Market
Global Inactivated Poultry Vaccines Market Research Report 2024
Poliovirus Vaccine Inactivated Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza Virus Vector Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Quadrivalent Flu Vaccine Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions